Atlas Trials

The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma

Clinical trial NCT00554515 · COMPLETED

Trial details

NCT number
NCT00554515
Sponsor
Beth Israel Deaconess Medical Center
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Renal Cell Carcinoma
Start date
2006-11-01
Primary completion
2013-10-31
Enrollment
123

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.